Kura Oncology KURA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.27M+5.4% | $17.34M-16.5% | $20.75M+35.7% | $15.29M+8.4% | $14.11M+4.7% | ||
| $262K— | —— | —— | —— | —— | ||
| $18M— | —— | —— | —— | —— | ||
| 98.6%— | —— | —— | —— | —— | ||
| $65.26M+1.3% | $64.41M-5.2% | $67.91M+8.2% | $62.79M+12.2% | $55.97M+7.1% | ||
| $31.56M— | —— | —— | —— | $22.84M+18.5% | ||
| $97.08M— | —— | —— | —— | $78.81M— | ||
| -$78.82M+8.6% | -$86.27M-7.8% | -$80M-10.1% | -$72.67M-12.3% | -$64.7M-188% | ||
| -431.5%+66.1pp | -497.6%-112pp | -385.5%+89.8pp | -475.3%-16.7pp | -458.6%-292pp | ||
| $336K-2.9% | $346K-12.0% | $393K+0.5% | $391K+2.4% | $382K-5.2% | ||
| $5.83M+2.5% | $5.69M-9.4% | $6.27M-9.5% | $6.94M-12.0% | $7.88M+39.2% | ||
| $5.49M+2.8% | $5.34M-9.2% | $5.88M-10.1% | $6.54M-12.7% | $7.5M+42.6% | ||
| -$73.33M+9.4% | -$80.93M-9.2% | -$74.12M-12.1% | -$66.12M-15.6% | -$57.2M-233% | ||
| $8K-88.7% | $71K— | —— | —— | $226K-55.2% | ||
| -$73.33M+9.5% | -$81M-9.3% | -$74.12M-12.1% | -$66.12M-15.1% | -$57.43M-199% | ||
| -401.5%+65.7pp | -467.2%-110pp | -357.2%+75.3pp | -432.5%-25.4pp | -407.1%-264pp | ||
| -$0.83+9.8% | -$0.92-8.2% | -$0.85-13.3% | -$0.75-13.6% | -$0.66-200% | ||
| -$0.83+9.8% | -$0.92-8.2% | -$0.85-13.3% | -$0.75-13.6% | -$0.66-200% | ||
| 88.6M+1.1% | 87.7M0.0% | 87.6M+0.1% | 87.6M+0.2% | 87.4M+1.5% | ||
| 88.6M+1.1% | 87.7M0.0% | 87.6M+0.1% | 87.6M+0.2% | 87.4M+1.5% | ||
| —— | $14.25K0.0% | $14.25K0.0% | $14.25K0.0% | $14.25K— | ||
| -$74.74M+7.6% | -$80.89M-9.4% | -$73.91M-11.3% | -$66.39M-16.0% | -$57.22M-192% | ||
| $5.83M+2.5% | $5.69M-9.4% | $6.27M-9.5% | $6.94M-12.0% | $7.88M+39.2% | ||
| -$1.4M— | —— | $207K+179% | -$263K-225% | $210K— | ||
| $18.27M+5.4% | $17.34M-16.5% | $20.75M+35.7% | $15.29M+8.4% | $14.11M+4.7% | ||
| -$78.82M+8.6% | -$86.27M-7.8% | -$80M-10.1% | -$72.67M-12.3% | -$64.7M-188% | ||
| -$78.46M+8.6% | -$85.87M-7.6% | -$79.83M-10.2% | -$72.44M-12.4% | -$64.46M-190% | ||
| -$78.46M+8.6% | -$85.87M-7.6% | -$79.83M-10.2% | -$72.44M-12.4% | -$64.46M-190% | ||
| -429.6%+65.7pp | -495.3%-111pp | -384.7%+89.1pp | -473.8%-17.0pp | -456.9%-292pp | ||
| -$78.82M+8.6% | -$86.27M-7.8% | -$80M-10.1% | -$72.67M-12.3% | -$64.7M-188% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kura Oncology's revenue?
- Kura Oncology (KURA) generated $71.6M in revenue over the trailing twelve months, up 31.4% year over year.
- Is Kura Oncology profitable?
- Kura Oncology is not currently profitable: it reported a net loss of $294.6M over the trailing twelve months, a -411.2% net margin.
- What is Kura Oncology's earnings per share?
- Kura Oncology's diluted EPS over the trailing twelve months is $-3.35.
- Where does Kura Oncology's income statement data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
